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Abstract
            Re-use of DDD pulse generators explanted from patients died of unrelated causes is
associated with an additional cost of two transvenous leads if implanted as DDD itself, and high
rate of infection according to some studies. We studied the clinical and economical aspects of
reutilization of explanted DDD pacemakers programmed to VDD mode. Out of 28 patients who
received VDD pacemaker during the period, October 2000- September 2001 in the Department
of Cardiology, PGIMER, Chandigarh, 5 poor patients were implanted with explanted DDD
pulse generators programmed to VDD mode. Each implantation was planned and carried out
according to a standard protocol. The age ranged from 45 to 75 (mean-61) years. The
indications for pacing were complete heart block (4) and second degree AV block (1). The
clinical profile, costs and complications, if any were noted and followed up at regular intervals.
The results were compared with patients who received new DDD pulse generators during this
period. The additional cost for the atrial lead was not required in these patients. None of these
patients had any local site infection. Compared to the two-lead system, the single lead system
provided more rapid implantation and minimized complications associated with placement of
an atrial lead. The explanted DDD pacemaker can be safely reused as VDD mode with same
efficacy in selected patient population. This is associated with lower cost and complications
compared to reimplantation as DDD itself.
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Introduction
            Technology is outpacing the financial resources available for health care all over the
world. Pacemakers are among the expensive devices, and when indicated properly they have no
alternative. In many instances pacemakers outlive the patients and it would be a waste to
dispose these pacemakers that are still in good condition having considerable battery life left
without allowing others to  benefit.   However  the   reuse of   pacemakers   is   associated   with
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widespread technical, medical, ethical and legal considerations.Reuse of DDD pulse generators
explanted from patients dying of unrelated causes is associated with an additional cost of two
transvenous leads, if reimplanted in DDD mode itself. There are also reports of unacceptably
high rates of infection associated with reuse of explanted pacemakers. We studied the clinical
and economical aspects of utilization of explanted DDD pacemakers programmed to VDD
mode.
Materials and methods
               During the period October 2000 to December 2001 (15 months) the patients who
received pacemakers in PGIMER, Chandigarh were studied. Out of these patients, those who
received generators explanted from patients who had died of unrelated causes were noted. We
used explanted dual chamber pulse generators (Medtronic, Prodigy DR, model 7860, bipolar)
after programming to VDD mode, with the use of new VDD lead (58-13.5-9F) in poor patients
who could not afford a new pulse generator. Appropriate preprocedural evaluation was done in
these patients to achieve optimal patient selection for VDD mode. The pulse generators had
been explanted postmortem from patients who died of causes other than pacemaker failure after
informed consent from the nearest relative. The generators were properly cleansed in antiseptic
solution and sterilized with ethylene oxide and reliably tested for function and battery life. The
recipient’s consent was also sought after proper explanation of the risks and benefits.
            These patients were followed up after one month of implantation initially and three
monthly thereafter. They were compared with those patients who received DDD pacing during
the same period regarding cost, complications and procedural time. To assess the quality of life
(QOL), a standard questionnaire (Table1) was given to the patients during their last follow up
visit of the study period. The questionnaire contained 7 questions, 3 related to the general QOL
and 4 specific to the pacemaker related symptoms. Each question contained 4 responses, the
individual score varying from 1-4 according to severity. The total score in each patient was
calculated.
Results
            During the study period 136 pacemakers were implanted in same number of patients in
this hospital, which included 53 dual chamber (DDD 25, VDD 28) and 83 single chamber
(VVI/ R 78, AAI/R 5) pacemakers. Indications for the implantation included sick sinus
syndrome   (31),   high-grade   AV   block   (94),   symptomatic   trifascicular   block   (9)   and
cardiomyopathy (2). 21 cases involved reuse of pacemakers, which included 9 cases of
reimplantation in the same patient (pacemaker infection-2, lead fracture or displacement-5, and
pacemaker extrusion-2) and 12 cases of reuse of pacemakers explanted postmortem (dual
chamber-8, single chamber-4).
            Out of 8 dual chamber pacemaker generators explanted, 5 programmable DDD pulse
generators were reimplanted in VDD mode. These 5 patients included one female and their age
varied from 45 to 75 (mean 61) years (Table 2). Four of them had complete heart block while
one had second-degree Mobitz-type II heart block. The battery life assessed prior to reuse
varied from 43 to 124 (mean 89.4) months. The average battery voltage at implantation was
2.77 volts. A new VDD lead (58-13.5-9F), which costs about 20,000/-, was used in all. This
reduced the extra amount spent on the two transvenous leads (2 x 18, 000/- =Rs 36,000/-) by
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  Table 1: Questionnaire for Quality of life
(QOL) assessment
A: General Quality of Life
1.    Inconvenience caused by the procedure                                           
                    Nil /minimal/moderate/severe
2.    Symptoms before and after pacemaker implantation
                    Disappeared /improved/unchanged/worsened
3.    Did you need a change in your profession?
         Positive adjustment/more strenuous work
         No adjustment/former occupation
         Minimal adjustment/less strenuous
         Major change/retired
B: Pacemaker related symptoms
                                Before implantation              After implantation
                                severe/moderate/mild no      severe/moderate/mild/no
1.    Fatigue 
2.    Dizzy spells
3.    Palpitation
4.    Breathlessness
Table 2: Baseline characteristics
Characteristics Explanted DDD New DDD
No. of patients
Male: Female
Age (yrs)
Follow up duration (months)
Indications 
    • Sick sinus syndrome
    • High degree AV block
    • Symptomatic trifascicular block
    • Cardiomyopathy (CMP) 
5
4:1
61
19.2
-
5
-
-
25
17: 8
48.3
17.4
5
14
4
2
Rs16, 000/- per patient. As the VDD lead required only a single lead introducer for its insertion,
an extra amount of Rs 2,000/- was also avoided making a net gain of Rs 18,000/-, i.e., 50% of
the total expenditure of refurbishment per patient.
            The fluoroscopy time spent for the procedure was also less compared to that used for
DDD  insertion.   None   of  these  5  patients  had  any  local  site   infection.   The  duration  of
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postprocedural hospital stay was not prolonged in these patients (5.2 vs. 7.4 days; NS). These
patients on follow up (mean follow up 19.2 months) showed normal atrial sensing and
ventricular pacing. The quality of life, assessed based on a standard questionnaire did not reveal
any significant difference between those received explanted pulse generator and newer one
(22.2 vs. 24.4 points; NS). There was no incidence of pacemaker related tachycardia,
pacemaker syndrome or lead displacement in any of these (Table 3).
Table 3: Follow-up results 
Characteristics Explanted
DDD
New DDD
Fluoroscopy time (minutes)
Postprocedural hospital stay (days)
Expense for pacing lead (Rs/-)
Complications
    • Local site infection
    • Lead displacement
Quality of life index
Mortality 
8.3
5.2
20,000
-
-
22.2
-
12.8
7.4
36,000
1(4%)
1(4%)
24.4(excluding patients with CMP)
1(unrelated cause)
                 
Discussion 
            We studied 5 patients who received explanted DDD programmable pulse generators,
which were programmed to VDD mode prior to implantation. Analysis of cost effectiveness
and safety in these poor and unaffordable patients revealed that these generators can be safely
and effectively used at a significantly lower cost.
            The rationale for the reuse of pacemakers is based on the following facts. The current
lithium battery pacemakers have an expected life greater than 10 yrs. In high-risk subgroups of
patients with coronary artery disease and atrioventricular block, the 3-year mortality approaches
60%1 and thus many pacemakers would have more than 5 years of life left when the recipients
die. Pringle et al reported a mortality rate of 58% within 2 years of last generator implant based
on a retrospective examination of 169 consecutive pacemaker patient-deaths2. It should also be
noted that in patients with severe cardiac diseases such as heart failure and cardiomyopathy,
more sophisticated pacemakers are often implanted, and these patients do die earlier from their
original disease. Thus the waste of pacemaker life is aggravated.
            Mugica et al reviewed over 3,500 patients who had a 10-year follow up and reported no
significant difference in the actuarial survival of those patients given explanted generator
compared to those received newer one  3. Rosengarten et al observed similar incidence of
pacemaker related complications and survival among new and refurbished pacemakers in a
prospective comparative study over a mean follow up period of 36 months4. Such experiences
have repeatedly confirmed that when properly carried out, re-use of pacemakers does not pose
any additional risk with considerable reduction in cost. The lack of widespread acceptance of
pacemaker re-use is, therefore, not alone due to technical or medical considerations, but is
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related to ethical and legal problems associated with this approach. 
            The ethical and legal issues involve both the retrieval of a still usable pacemaker from a
deceased patient and the selection of the patient to receive such a pacemaker. In countries such
as Sweden, pacemakers are considered to be the property of the state and can be removed
routinely without the need for consent from the families of patients who have died. In many
other countries including Canada, US and India, once the pacemaker has been implanted
regardless of the source of funding for this procedure, the device is considered to belong to the
patient. Retrieval of such a device therefore requires the consent of the next of kin or the living
will of the patient. In view of theoretical risks of reimplantation of cadaveric explants, informed
consent of the recipient also should be sought, after proper explanation of possible risks
involved in the re-use.
            The clinical problem of reuse of pacemaker in the recipient is mainly based on the rate
of infection and battery life. The risk of re-use is that an instrument might be improperly
selected due to an inaccurate history of use, or improperly cleansed, tested or sterilized.
Explanted pacemakers should be considered for re-use only when the reliable clinical record
indicates that the instrument has had no malfunction and has an arbitrarily set minimum battery
life of 5 years. After proper electronic testing, the pulse generators are to be washed under
sterile conditions in distilled water and then gas sterilized with ethylene oxide for two hours at
55°C and 60% humidity. The device is released for implantation after essential aeration for 48
hours at 55°C in an aeration device or in the appropriate sterilizer. Mond et al described a high
rate of infection with the reuse of explanted pacemakers5. Based on a retrospective case control
study, which involved 100 patients who received re-used pacemakers, Linde et al concluded
that the re-use of pacemakers could be carried out without increased risk to the patient provided
a proper routine for technical control and sterilization is followed6. Experiences of other
authors have also confirmed the short- and long-term safety of re-use of cadaveric explants7,8,9. 
            None of our patients had local site infection. Battery life of the pulse generators was
properly assessed prior to implantation by a pacing system analyzer in all. The average battery
life of these 5 pulse generators at the time of implantation was 89.4months (at 60 bpm, output 4
V, pulse width 0.4 ms and VDD mode). The re-use as VDD system resulted in avoiding the
need of atrial lead placement leading to reduction in fluoroscopy time and virtual nonexistence
of complications related to atrial lead, apart from reducing the cost significantly. The cost
reduction by   Rs 16,000/- per patient was significant considering the baseline economic status
of these poor patients. There was no significant difference in the duration of hospital stay, need
of antibiotics or additional cost to the patients. Proper atrial sensing, the most essential
component of VDD pacing was also unaltered on follow up. Similarly, none of these patients
had pacemaker syndrome, pacemaker-mediated tachycardia or atrial arrhythmias on follow up.
There was no significant difference in the quality of life score between those received explanted
pulse generator and newer one.
             This study has some limitation in that the patient sample is small due to obvious
problems mentioned. We didn’t assess the incidence of VVI pacing by Holter monitoring on
follow up. However, with good sinus node function, programmed lower rate of 50 bpm and
good atrial tracking noted at each follow up visit, significant VVI pacing in between is unlikely,
though  we  cannot  categorically  deny  such an occurrence. However, this issue is largely
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overwhelmed by the fact that most recipients were extremely poor and they were not in a
position to afford anything more than the cost of the new electrode.
            The re-use of pacemakers is not carried out routinely, as many physicians and affordable
patients do not encourage it usually. The manufacturers are also understandably reluctant to
participate in refurbishing used pacemakers and the pacemaker warranty disclaims liability to
anyone except the first recipient. Yokoyama reported that re-use of explanted pacemaker
constituted only 0.1% of all implanted pacemaker units in Japan in 199210. The corresponding
figures from India are not available.
             We could not find many publications on the re-use of explanted pacemakers from our
country. Panja et al noted that the efficacy of re-used pacemaker was highly comparable to that
of newly implanted one in terms of morbidity and mortality. Re-use in the same patient, but not
reuse of cadaveric explants was associated with high rate of infection in their study7. Sethi et al
re-used 13 explanted generators out of 42 refurbished pacemakers. There was no pulse
generator failure or adverse reactions among these during a mean duration follow up of 34
months8.  Balachander et al also reported the safety and efficacy of refurbished pacemakers in
140 implantations9.   Hence, the pacemaker reuse needs to be encouraged in developing
countries and rationale for reuse should be purely economical. 
            Concluding, the explanted programmable dual chamber pacemakers can be safely re-
used in VDD mode with same efficacy in selected patient population, at significantly lower
cost.
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